Контроль гликемии у пациентов с сахарным диабетом на программном гемодиализе
Контроль гликемии у пациентов с сахарным диабетом на программном гемодиализе
Лобанова К.Г., Северина А.С., Мартынов С.А. и др. Контроль гликемии у пациентов с сахарным диабетом на программном гемодиализе. Терапевтический архив. 2019; 91 (10): 124–134. DOI: 10.26442/00403660.2019.10.000352
________________________________________________
Lobanova K.G., Severina A.S., Martinov S.A., et al. Glycemic control in patients with diabetes mellitus on hemodialysis. Therapeutic Archive. 2019; 91 (10): 124–134. DOI: 10.26442/00403660.2019.10.000352
Контроль гликемии у пациентов с сахарным диабетом на программном гемодиализе
Лобанова К.Г., Северина А.С., Мартынов С.А. и др. Контроль гликемии у пациентов с сахарным диабетом на программном гемодиализе. Терапевтический архив. 2019; 91 (10): 124–134. DOI: 10.26442/00403660.2019.10.000352
________________________________________________
Lobanova K.G., Severina A.S., Martinov S.A., et al. Glycemic control in patients with diabetes mellitus on hemodialysis. Therapeutic Archive. 2019; 91 (10): 124–134. DOI: 10.26442/00403660.2019.10.000352
Достижение стабилизации показателей углеводного обмена у пациентов с сахарным диабетом (СД), получающих заместительную почечную терапию (ЗПТ) с помощью программного гемодиализа (ГД), является существенной проблемой в эндокринологии. Это связано с наличием у данной когорты пациентов множества факторов, влияющих на уровень гликемии, фармакокинетику лекарственных средств, эффективность контроля гликемии. На данный момент наиболее эффективным методом контроля гликемии у пациентов с СД 2-го типа (СД2) на ГД является инсулинотерапия в базис-болюсном режиме аналогами человеческих инсулинов. Применение пероральных сахароснижающих препаратов существенно ограничено. Гликированный гемоглобин (HbA1c) остается основным параметром контроля гликемии. Одновременное использование суточного мониторирования гликемии позволяет оценить истинное состояние углеводного обмена и проводить своевременную коррекцию терапии с целью достижения целевых показателей гликемии и минимизации риска развития гипогликемических эпизодов. В настоящее время описаны другие маркеры контроля гликемии, такие как гликированный альбумин и фруктозамин. Однако в рутинной практике на данный момент эти показатели не используются из-за отсутствия достаточной доказательной базы возможности их применения у данной когорты пациентов.
Achievement of stabilization of carbohydrate metabolism in patients with diabetes mellitus, receiving renal replacement therapy with hemodialysis, is a significant problem in endocrinology. It has to do with multiple factors of this cohort of patients, which affect the level of glycemia, pharmacokinetic of drugs, the efficiency of glycemic control. At the moment, the most efficiency method of glycemic control in patients with type 2 diabetes mellitus on hemodialysis is insulin therapy in the basis-bolus regime by analogues of human insulin. The use of oral hypoglycemic agents is significantly limited. The hemoglobin A1c (HbA1c) remains the main parameter of glycemic control. The simultaneous use of continuous glucose monitoring allows to reveal the true level of glucose of the blood and to carry out the timely correction of therapy in order to achieve targets for glycemic control and to decrease the risk of hypoglycemic episodes. At the moment other glycemic control markers such as glycated albumin and fructosamine are described. However, in routine practice at the moment these indicators are not used due to the lack of sufficient evidentiary base of their use in this cohort of patients.
1. Шамхалова М.Ш., Викулова О.К., Железнякова А.В. и др. Эпидемиология хронической болезни почек в Российской Федерации по данным Федерального регистра взрослых пациентов с сахарным диабетом (2013–2016 гг.). Сахарный диабет. 2018;21(3):160-9 [Shamkhalova MSh, Vikulova OK, Zheleznyakova AV, et al. Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal diabetes register (2013–2016). Sakharnyi Diabet = Diabetes Mellitus. 2018;21(3):160-9 (In Russ.)]. doi: 10.14341/DM9392
2. Томилина Н.А., Андрусев А.М., Перегудова Н.Г. и др. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 2010–2015 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Часть первая. М., 2017 [Tomilina NA, Andrusev AM, Peregudova NG, et al. Renal replacement therapy for End Stage Renal Disease in Russian Federation, 2010–2015 Russian National Renal Replacement Therapy Registry Report of Russian Public Organization of Nephrologists "Russian Dialysis Society". Part 1. Moscow, 2017 (In Russ.)]. doi: 10.28996/1680-4422-2017-4Suppl-1-95
3. Дедов И.И., ред. Диализная терапия у больных с сахарным диабетом. М.: Министерство здравоохранения и социального развития Российской Федерации, 2009 [Dedov II, ed. Dialysis therapy in patients with diabetes mellitus. Moscow: Ministry of health and social development of the Russian Federation, 2009 (In Russ.)].
4. Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11(5):302-13. doi: 10.1038/nrneph.2015.38
5. Wakino S, Minakuchi H, Miya K, et al. Aldosterone and Insulin Resistance: Vicious Combination in Patients on Maintenance Hemodialysis. Ther Apher Dial. 2018;22(2):142-51. doi: 10.1111/1744-9987.12632
6. Sudha MJ, Salam HS, Viveka S, et al. Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. J Nat Sci Biol Med. 2017;8(1):64-8. doi: 10.4103/0976-9668.198348
7. Sobngwi E, Enoru S, Ashuntantang G, et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33(7):1409-12. doi: 10.2337/dc09-2176
8. Nakao T, Inaba M, Abe M, et al. Best practice for diabetic patients on hemodialysis 2012. Ther Apher Dial. 2015;19 Suppl 1:40-66. doi: 10.1111/1744-9987.12299
9. Guthoff M, Wagner R, Vosseler D, et al. Impact of end-stage renal disease on glucose metabolism – a matched cohort analysis. Nephrol Dial Transplant. 2017;32(4):670-6. doi: 10.1093/ndt/gfx018
10. Rhee CM, Leung AM, Kovesdy CP, et al. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27(2):135-45. doi: 10.1111/sdi.12198
11. Tzamaloukas AH. Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Adv Peritoneal Dial. 1996;12:171-5.
12. Sinha N, Mishra TK, Singh T, Gupta N. Effect of iron deficiency anemia on hemoglobin A1 levels. Ann Lab Med. 2012;32:17-22.
13. Sharif A, Baboola K. Diagnostic application of the A1 assay in renal disease. J Am Soc Nephrol. 2010;21:383-94.
14. Park J, Lertdumrongluk P, Molnar MZ, et al. Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon. Curr Diab Rep. 2012;12(4):432-9. doi: 10.1007/s11892-012-0286-3
15. Ricks J, Molnar MZ, Kovesdy CP, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61(3):708-15. doi: 10.2337/db11-1015
16. Abe M, Hamano T, Hoshino J, et al. Is there a "burnt-out diabetes" phenomenon in patients on hemodialysis? Diabetes Res Clin Pract. 2017;130:211-20. doi: 10.1016/j.diabres.2017.06.012
17. Hoshino J, Larkina M, Karaboyas A, et al. Unique hemoglobin A1c level distribution and its relationship with mortality in diabetic hemodialysis patients. Kidney Int. 2017;92(2):497-503. doi: 10.1016/j.kint.2017.02.008
18. Ramirez SP, McCullough KP, Thumma JR, et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care. 2012;35(12):2527-32. doi: 10.2337/dc12-0573
19. Yoo DE, Park JT, Oh HJ, et al. Good glycemic control is associated with better survival in diabetic patients on peritoneal dialysis: a prospective observational study. PLoS One. 2012;7(1):e30072. doi: 10.1371/journal.pone.0030072
20. Kim Y, Park JC, Molnar MZ, et al. Correlates of low hemoglobin A1c in maintenance hemodialysis patients. Int Urol Nephrol. 2013;45(4):1079-90. doi: 10.1007/s11255-012-0208-y
21. Bedi R, Dr Chowdhury TA, El-Sherbini N, et al. JBDS-IP Management of adults with diabetes on the haemodialysis unit. 2016 Apr. Brit J Diabetes. 2016 Apr.;16(2):69-77.
22. American Diabetes Association. Standarts of Medical Care in Diabetes – 2018. Diabetes Care. 2018:41(S.1). doi: 10.2337/dc18-Sint01
23. Дедов И.И., Шестакова М.В., Майоров А.Ю., ред. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. M.: Министерство здравоохранения и социального развития Российской Федерации, 2017 [Dedov II, Shestakova MV, Mayorov AYu, eds. Standards of specialized diabetes care. Moscow: Ministry of health and social development of the Russian Federation, 2017 (In Russ.)].
24. Новицкий В.В., Гольдберг Е.Д. и др., ред. Патофизиология. М.: ГЭОТАР-Медиа, 2009. Т. 1. 848 с. Глава 12.6.5 [Novitcki VV, Goldberg ED, et al. Pathophysiology. Moscow: GEOTAR-Media, 2009. Vol. 1. 848 p. (In Russ.)].
25. Андрушкевич В.В. Биохимические показатели крови, их рефересные значения, причины изменения уровня в сыворотке крови. Новосибирск, 2006. 29 с. [Andrushkevich VV. Biochemical blood parameters, their reference values, causes of changes in serum levels. Novosibirsk, 2006. 29 p. (In Russ.)].
26. Shafi T, Sozio SM, Plantinga LC, et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care. 2013;36(6):1522-33. doi: 10.2337/dc12-1896
27. Okada T, Nakao T, Matsumoto H, et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med. 2007;46:807-14.
28. Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton). 2008;13:278-83. doi: 10.1111/j.1440-1797.2007.00864.x
29. Klonoffa DC, Ahnb D, Drincicc A. Continuous glucose monitoring: A review of the technology and clinical use. Diabetes Res Clin Pract. 2017;133:178-92. doi: 10.1016/j.diabres.2017.08.005
30. Gai M, Merlo I, Dellepiane S, et al. Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis. Blood Purif. 2014;38(1):68-73. doi: 10.1159/000362863
31. Képénékian L, Smagala A, Meyer L, et al. Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study. Clin Nephrol. 2014;82(4):240-6. doi: 10.5414/CN108280
32. Joubert M, Fourmy C, Henri P, et al. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015;107(3):348-54. doi: 10.1016/j.diabres.2015.01.026
33. Ólafsdóttir AF, Polonsky W, Bolinder J, et al. A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technol Ther. 2018;20(4):274-84. doi: 10.1089/dia.2017.0363
34. Mirani M, Berra C, Finazzi S, et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther. 2010;12(10):749-53. doi: 10.1089/dia.2010.0052
35. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391(10128):1367-77. doi: 10.1016/S0140-6736(18)30297-6
36. Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther. 2000;67(1):7-15. doi: 10.1067/mcp.2000.103973
37. Hasslacher C; Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26(3):886-91.
38. Terawaki Y, Nomiyama T, Akehi Y, et al. The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr. 2013;5(1):10. doi: 10.1186/1758-5996-5-10
39. Osonoi T, Saito M, Tamasawa A, et al. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study. PLoS One. 2014;9(12):e113468. doi: 10.1371/journal.pone.0113468
40. Idorn T, Knop FK, Jørgensen MB, et al. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care. 2016;39(2):206-13. doi: 10.2337/dc15-1025
41. Park SH, Nam JY, Han E, et al. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine (Baltimore). 2016;95(32):e4543. doi: 10.1097/MD.0000000000004543
42. Nakamura Y, Hasegawa H, Tsuji M, et al. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes. 2015;6(6):840-9. doi: 10.4239/wjd.v6.i6.840
43. Padmanabhan A, Velayudham B, Vijaykumar N, et al. Evaluation of glycemic status during the days of hemodialysis using dialysis solutions with and without glucose. Saudi J Kidney Dis Transpl. 2018;29(5):1021-7. doi: 10.4103/1319-2442.243951
44. Burmeister JE, Miltersteiner Dda R, Burmeister BO, et al. Risk of hypoglycemia during hemodialysis in diabetic patients is related to lower pre-dialysis glycemia. Arch Endocrinol Metab. 2015;59(2):137-40. doi: 10.1590/2359-3997000000026
45. Burmeister JE, Scapini A, da Rosa Miltersteiner D, et al. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis. Nephrol Dial Transplant. 2007;22(4):1184-9. doi: 10.1093/ndt/gfl710
46. Raimann JG, Kruse A, Thijssen S, et al. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant. 2012;27(4):1559-68. doi: 10.1093/ndt/gfr520
________________________________________________
1. [Shamkhalova MSh, Vikulova OK, Zheleznyakova AV, et al. Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal diabetes register (2013–2016). Sakharnyi Diabet = Diabetes Mellitus. 2018;21(3):160-9 (In Russ.)]. doi: 10.14341/DM9392
2. [Tomilina NA, Andrusev AM, Peregudova NG, et al. Renal replacement therapy for End Stage Renal Disease in Russian Federation, 2010–2015 Russian National Renal Replacement Therapy Registry Report of Russian Public Organization of Nephrologists "Russian Dialysis Society". Part 1. Moscow, 2017 (In Russ.)]. doi: 10.28996/1680-4422-2017-4Suppl-1-95
3. [Dedov II, ed. Dialysis therapy in patients with diabetes mellitus. Moscow: Ministry of health and social development of the Russian Federation, 2009 (In Russ.)].
4. Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11(5):302-13. doi: 10.1038/nrneph.2015.38
5. Wakino S, Minakuchi H, Miya K, et al. Aldosterone and Insulin Resistance: Vicious Combination in Patients on Maintenance Hemodialysis. Ther Apher Dial. 2018;22(2):142-51. doi: 10.1111/1744-9987.12632
6. Sudha MJ, Salam HS, Viveka S, et al. Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. J Nat Sci Biol Med. 2017;8(1):64-8. doi: 10.4103/0976-9668.198348
7. Sobngwi E, Enoru S, Ashuntantang G, et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33(7):1409-12. doi: 10.2337/dc09-2176
8. Nakao T, Inaba M, Abe M, et al. Best practice for diabetic patients on hemodialysis 2012. Ther Apher Dial. 2015;19 Suppl 1:40-66. doi: 10.1111/1744-9987.12299
9. Guthoff M, Wagner R, Vosseler D, et al. Impact of end-stage renal disease on glucose metabolism – a matched cohort analysis. Nephrol Dial Transplant. 2017;32(4):670-6. doi: 10.1093/ndt/gfx018
10. Rhee CM, Leung AM, Kovesdy CP, et al. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27(2):135-45. doi: 10.1111/sdi.12198
11. Tzamaloukas AH. Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Adv Peritoneal Dial. 1996;12:171-5.
12. Sinha N, Mishra TK, Singh T, Gupta N. Effect of iron deficiency anemia on hemoglobin A1 levels. Ann Lab Med. 2012;32:17-22.
13. Sharif A, Baboola K. Diagnostic application of the A1 assay in renal disease. J Am Soc Nephrol. 2010;21:383-94.
14. Park J, Lertdumrongluk P, Molnar MZ, et al. Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon. Curr Diab Rep. 2012;12(4):432-9. doi: 10.1007/s11892-012-0286-3
15. Ricks J, Molnar MZ, Kovesdy CP, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61(3):708-15. doi: 10.2337/db11-1015
16. Abe M, Hamano T, Hoshino J, et al. Is there a "burnt-out diabetes" phenomenon in patients on hemodialysis? Diabetes Res Clin Pract. 2017;130:211-20. doi: 10.1016/j.diabres.2017.06.012
17. Hoshino J, Larkina M, Karaboyas A, et al. Unique hemoglobin A1c level distribution and its relationship with mortality in diabetic hemodialysis patients. Kidney Int. 2017;92(2):497-503. doi: 10.1016/j.kint.2017.02.008
18. Ramirez SP, McCullough KP, Thumma JR, et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care. 2012;35(12):2527-32. doi: 10.2337/dc12-0573
19. Yoo DE, Park JT, Oh HJ, et al. Good glycemic control is associated with better survival in diabetic patients on peritoneal dialysis: a prospective observational study. PLoS One. 2012;7(1):e30072. doi: 10.1371/journal.pone.0030072
20. Kim Y, Park JC, Molnar MZ, et al. Correlates of low hemoglobin A1c in maintenance hemodialysis patients. Int Urol Nephrol. 2013;45(4):1079-90. doi: 10.1007/s11255-012-0208-y
21. Bedi R, Dr Chowdhury TA, El-Sherbini N, et al. JBDS-IP Management of adults with diabetes on the haemodialysis unit. 2016 Apr. Brit J Diabetes. 2016 Apr.;16(2):69-77.
22. American Diabetes Association. Standarts of Medical Care in Diabetes – 2018. Diabetes Care. 2018:41(S.1). doi: 10.2337/dc18-Sint01
23. [Dedov II, Shestakova MV, Mayorov AYu, eds. Standards of specialized diabetes care. Moscow: Ministry of health and social development of the Russian Federation, 2017 (In Russ.)].
24. [Novitcki VV, Goldberg ED, et al. Pathophysiology. Moscow: GEOTAR-Media, 2009. Vol. 1. 848 p. (In Russ.)].
25. [Andrushkevich VV. Biochemical blood parameters, their reference values, causes of changes in serum levels. Novosibirsk, 2006. 29 p. (In Russ.)].
26. Shafi T, Sozio SM, Plantinga LC, et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care. 2013;36(6):1522-33. doi: 10.2337/dc12-1896
27. Okada T, Nakao T, Matsumoto H, et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med. 2007;46:807-14.
28. Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton). 2008;13:278-83. doi: 10.1111/j.1440-1797.2007.00864.x
29. Klonoffa DC, Ahnb D, Drincicc A. Continuous glucose monitoring: A review of the technology and clinical use. Diabetes Res Clin Pract. 2017;133:178-92. doi: 10.1016/j.diabres.2017.08.005
30. Gai M, Merlo I, Dellepiane S, et al. Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis. Blood Purif. 2014;38(1):68-73. doi: 10.1159/000362863
31. Képénékian L, Smagala A, Meyer L, et al. Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study. Clin Nephrol. 2014;82(4):240-6. doi: 10.5414/CN108280
32. Joubert M, Fourmy C, Henri P, et al. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015;107(3):348-54. doi: 10.1016/j.diabres.2015.01.026
33. Ólafsdóttir AF, Polonsky W, Bolinder J, et al. A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technol Ther. 2018;20(4):274-84. doi: 10.1089/dia.2017.0363
34. Mirani M, Berra C, Finazzi S, et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther. 2010;12(10):749-53. doi: 10.1089/dia.2010.0052
35. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391(10128):1367-77. doi: 10.1016/S0140-6736(18)30297-6
36. Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther. 2000;67(1):7-15. doi: 10.1067/mcp.2000.103973
37. Hasslacher C; Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26(3):886-91.
38. Terawaki Y, Nomiyama T, Akehi Y, et al. The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr. 2013;5(1):10. doi: 10.1186/1758-5996-5-10
39. Osonoi T, Saito M, Tamasawa A, et al. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study. PLoS One. 2014;9(12):e113468. doi: 10.1371/journal.pone.0113468
40. Idorn T, Knop FK, Jørgensen MB, et al. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care. 2016;39(2):206-13. doi: 10.2337/dc15-1025
41. Park SH, Nam JY, Han E, et al. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine (Baltimore). 2016;95(32):e4543. doi: 10.1097/MD.0000000000004543
42. Nakamura Y, Hasegawa H, Tsuji M, et al. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes. 2015;6(6):840-9. doi: 10.4239/wjd.v6.i6.840
43. Padmanabhan A, Velayudham B, Vijaykumar N, et al. Evaluation of glycemic status during the days of hemodialysis using dialysis solutions with and without glucose. Saudi J Kidney Dis Transpl. 2018;29(5):1021-7. doi: 10.4103/1319-2442.243951
44. Burmeister JE, Miltersteiner Dda R, Burmeister BO, et al. Risk of hypoglycemia during hemodialysis in diabetic patients is related to lower pre-dialysis glycemia. Arch Endocrinol Metab. 2015;59(2):137-40. doi: 10.1590/2359-3997000000026
45. Burmeister JE, Scapini A, da Rosa Miltersteiner D, et al. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis. Nephrol Dial Transplant. 2007;22(4):1184-9. doi: 10.1093/ndt/gfl710
46. Raimann JG, Kruse A, Thijssen S, et al. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant. 2012;27(4):1559-68. doi: 10.1093/ndt/gfr520